|
Volumn 49, Issue 1, 2005, Pages 195-201
|
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BACTERICIDE;
GLYCOPEPTIDE;
PLACEBO;
TELAVANCIN;
UNCLASSIFIED DRUG;
ADULT;
AREA UNDER THE CURVE;
ARTICLE;
BACTERICIDAL ACTIVITY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIZZINESS;
DOUBLE BLIND PROCEDURE;
DRUG BLOOD LEVEL;
DRUG HALF LIFE;
DRUG SAFETY;
FLUSHING;
GRAM POSITIVE BACTERIUM;
HEADACHE;
HUMAN;
HUMAN EXPERIMENT;
INJECTION SITE REACTION;
MALE;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;
NAUSEA;
NORMAL HUMAN;
PRIORITY JOURNAL;
PRURITUS;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
STEADY STATE;
STREPTOCOCCUS PNEUMONIAE;
URTICARIA;
ADOLESCENT;
ADULT;
AMINOGLYCOSIDES;
ANTI-BACTERIAL AGENTS;
AREA UNDER CURVE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
HALF-LIFE;
HUMANS;
INJECTIONS, INTRAVENOUS;
MALE;
METHICILLIN RESISTANCE;
MICROBIAL SENSITIVITY TESTS;
MIDDLE AGED;
SERUM BACTERICIDAL TEST;
STAPHYLOCOCCUS AUREUS;
STREPTOCOCCUS PNEUMONIAE;
|
EID: 11244316714
PISSN: 00664804
EISSN: None
Source Type: Journal
DOI: 10.1128/AAC.49.1.195-201.2005 Document Type: Article |
Times cited : (144)
|
References (9)
|